Flputnam Investment Management Co. Cuts Stock Holdings in Sanofi (NASDAQ:SNY)

Flputnam Investment Management Co. lowered its stake in Sanofi (NASDAQ:SNY) by 24.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,109 shares of the company’s stock after selling 1,658 shares during the period. Flputnam Investment Management Co.’s holdings in Sanofi were worth $246,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Synergy Asset Management LLC purchased a new position in Sanofi in the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the period. Sierra Ocean LLC purchased a new position in shares of Sanofi in the fourth quarter worth $44,000. Finally, Versant Capital Management Inc bought a new stake in Sanofi during the 4th quarter valued at $54,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Up 3.8 %

NASDAQ:SNY opened at $56.52 on Tuesday. The company has a 50-day moving average price of $51.81 and a 200-day moving average price of $52.61. The stock has a market cap of $143.44 billion, a price-to-earnings ratio of 22.70, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.